Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

M Mansfeld; A Skrahina; L Shepherd; A Schultze; A M Panteleev; R F Miller; J M Miro; I Zeltina; S Tetradov; H Furrer; O Kirk; A Grzeszczuk; N Bolokadze; A Matteelli; F A Post; J D Lundgren; A Mocroft; Anne Marie Werlinrud Efsen; D N Podlekareva; TB:HIV study group in EuroCoord

doi:10.1111/hiv.12256

Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

M Mansfeld, A Skrahina, L Shepherd, A Schultze, A M Panteleev, R F Miller, J M Miro, I Zeltina, S Tetradov, H Furrer, O Kirk, A Grzeszczuk, N Bolokadze, A Matteelli, F A Post, J D Lundgren, A Mocroft, Anne Marie Werlinrud Efsen, D N Podlekareva, TB:HIV study group in EuroCoord

Department of Clinical Medicine

18 Citations (Scopus)

Abstract

Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). Methods: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. Results: Respondent centres in EE comprised: Belarus (n=3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P<0.001) and less often provided by the same doctors (41% versus 90%, respectively; P=0.002), whereas regular screening of HIV-infected patients for TB (80% versus 40%, respectively; P=0.037) and directly observed treatment (88% versus 20%, respectively; P<0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P<0.001). Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfected patients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.

Original language	English
Journal	HIV Medicine
Volume	16
Issue number	9
Pages (from-to)	544-52
Number of pages	9
ISSN	1464-2662
DOIs	https://doi.org/10.1111/hiv.12256
Publication status	Published - 1 Oct 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/hiv.12256

hiv.12256Final published version, 367 KB

Cite this

Mansfeld, M., Skrahina, A., Shepherd, L., Schultze, A., Panteleev, A. M., Miller, R. F., Miro, J. M., Zeltina, I., Tetradov, S., Furrer, H., Kirk, O., Grzeszczuk, A., Bolokadze, N., Matteelli, A., Post, F. A., Lundgren, J. D., Mocroft, A., Efsen, A. M. W., Podlekareva, D. N., & TB:HIV study group in EuroCoord (2015). Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe. HIV Medicine, 16(9), 544-52. https://doi.org/10.1111/hiv.12256

Mansfeld, M, Skrahina, A, Shepherd, L, Schultze, A, Panteleev, AM, Miller, RF, Miro, JM, Zeltina, I, Tetradov, S, Furrer, H, Kirk, O, Grzeszczuk, A, Bolokadze, N, Matteelli, A, Post, FA, Lundgren, JD, Mocroft, A, Efsen, AMW, Podlekareva, DN & TB:HIV study group in EuroCoord 2015, 'Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe', HIV Medicine, vol. 16, no. 9, pp. 544-52. https://doi.org/10.1111/hiv.12256

@article{46ae18534ced46f3a36ae9474bef6b57,

title = "Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe",

abstract = "Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). Methods: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. Results: Respondent centres in EE comprised: Belarus (n=3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P<0.001) and less often provided by the same doctors (41% versus 90%, respectively; P=0.002), whereas regular screening of HIV-infected patients for TB (80% versus 40%, respectively; P=0.037) and directly observed treatment (88% versus 20%, respectively; P<0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P<0.001). Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfected patients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.",

author = "M Mansfeld and A Skrahina and L Shepherd and A Schultze and Panteleev, {A M} and Miller, {R F} and Miro, {J M} and I Zeltina and S Tetradov and H Furrer and O Kirk and A Grzeszczuk and N Bolokadze and A Matteelli and Post, {F A} and Lundgren, {J D} and A Mocroft and Efsen, {Anne Marie Werlinrud} and Podlekareva, {D N} and {TB:HIV study group in EuroCoord}",

note = "{\textcopyright} 2015 British HIV Association.",

year = "2015",

month = oct,

day = "1",

doi = "10.1111/hiv.12256",

language = "English",

volume = "16",

pages = "544--52",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

AU - Mansfeld, M

AU - Skrahina, A

AU - Shepherd, L

AU - Schultze, A

AU - Panteleev, A M

AU - Miller, R F

AU - Miro, J M

AU - Zeltina, I

AU - Tetradov, S

AU - Furrer, H

AU - Kirk, O

AU - Grzeszczuk, A

AU - Bolokadze, N

AU - Matteelli, A

AU - Post, F A

AU - Lundgren, J D

AU - Mocroft, A

AU - Efsen, Anne Marie Werlinrud

AU - Podlekareva, D N

AU - TB:HIV study group in EuroCoord

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). Methods: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. Results: Respondent centres in EE comprised: Belarus (n=3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P<0.001) and less often provided by the same doctors (41% versus 90%, respectively; P=0.002), whereas regular screening of HIV-infected patients for TB (80% versus 40%, respectively; P=0.037) and directly observed treatment (88% versus 20%, respectively; P<0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P<0.001). Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfected patients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.

AB - Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). Methods: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. Results: Respondent centres in EE comprised: Belarus (n=3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P<0.001) and less often provided by the same doctors (41% versus 90%, respectively; P=0.002), whereas regular screening of HIV-infected patients for TB (80% versus 40%, respectively; P=0.037) and directly observed treatment (88% versus 20%, respectively; P<0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P<0.001). Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfected patients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.

U2 - 10.1111/hiv.12256

DO - 10.1111/hiv.12256

M3 - Journal article

C2 - 25959854

SN - 1464-2662

VL - 16

SP - 544

EP - 552

JO - HIV Medicine

JF - HIV Medicine

IS - 9

ER -

Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this